Increased Serum Soluble OX40 in Patients with Systemic Sclerosis

• Published in: Journal of rheumatology 2008-12, Vol.35 (12), p.2359-2362
• Main Authors: KOMURA, Kazuhiro, YOSHIZAKI, Ayumi, FUJIMOTO, Manabu, TAKEHARA, Kazuhiko, SATO, Shinichi, KODERA, Masanari, IWATA, Yohei, OGAWA, Fumihide, SHIMIZU, Kazuhiro, WAYAKU, Takamasa, YUKAMI, Toru, MURATA, Maki, HASEGAWA, Minoru
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Biomarkers - blood; Case-Control Studies; Child; Child, Preschool; Diseases of the osteoarticular system; Female; Humans; Lupus Erythematosus, Systemic - blood; Male; Medical sciences; Middle Aged; OX40 Ligand - blood; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Scleroderma, Diffuse - blood; Scleroderma, Limited - blood; Young Adult
• ISSN: 0315-162X; 1499-2752
• DOI: 10.3899/jrheum.080120

Objective To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease. Key Indexing Terms: SYSTEMIC SCLEROSIS OX40 T LYMPHOCYTES